- Home
- USLM vs ICUI Comparison
USLM vs ICUI Comparison
Compare USLM & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USLM
- ICUI
- Stock Information
- Founded
- USLM 1948
- ICUI 1984
- Country
- USLM United States
- ICUI United States
- Employees
- USLM N/A
- ICUI N/A
- Industry
- USLM Other Metals and Minerals
- ICUI Medical/Dental Instruments
- Sector
- USLM Industrials
- ICUI Health Care
- Exchange
- USLM Nasdaq
- ICUI Nasdaq
- Market Cap
- USLM N/A
- ICUI 3.6B
- IPO Year
- USLM N/A
- ICUI 1992
- Fundamental
- Price
- USLM $89.11
- ICUI $139.11
- Analyst Decision
- USLM
- ICUI Buy
- Analyst Count
- USLM 0
- ICUI 4
- Target Price
- USLM N/A
- ICUI $199.67
- AVG Volume (30 Days)
- USLM 96.4K
- ICUI 288.3K
- Earning Date
- USLM 04-29-2025
- ICUI 05-06-2025
- Dividend Yield
- USLM 0.27%
- ICUI N/A
- EPS Growth
- USLM 45.21
- ICUI N/A
- EPS
- USLM 3.79
- ICUI N/A
- Revenue
- USLM $317,721,000.00
- ICUI $2,382,046,000.00
- Revenue This Year
- USLM N/A
- ICUI $0.21
- Revenue Next Year
- USLM N/A
- ICUI $2.47
- P/E Ratio
- USLM $23.78
- ICUI N/A
- Revenue Growth
- USLM 12.94
- ICUI 5.44
- 52 Week Low
- USLM $57.32
- ICUI $93.36
- 52 Week High
- USLM $159.53
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- USLM 39.48
- ICUI 40.91
- Support Level
- USLM $91.57
- ICUI $142.83
- Resistance Level
- USLM $98.78
- ICUI $152.06
- Average True Range (ATR)
- USLM 3.58
- ICUI 5.75
- MACD
- USLM 0.55
- ICUI 0.51
- Stochastic Oscillator
- USLM 28.69
- ICUI 52.59
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.